• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Febrile Neutropenia - Pipeline Review, H2 2012 Product Image

Febrile Neutropenia - Pipeline Review, H2 2012

  • ID: 2233836
  • August 2012
  • 35 pages
  • Global Markets Direct

Febrile Neutropenia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Febrile Neutropenia - Pipeline Review, H2 2012', provides an overview of the Febrile Neutropenia therapeutic pipeline. This report provides information on the therapeutic development for Febrile Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Febrile Neutropenia. 'Febrile Neutropenia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Febrile Neutropenia.
- A review of the Febrile Neutropenia products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Febrile Neutropenia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Febrile Neutropenia 7
Febrile Neutropenia Therapeutics under Development by Companies 9
Febrile Neutropenia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Febrile Neutropenia Therapeutics – Products under Development by Companies 14
Febrile Neutropenia Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Febrile Neutropenia Therapeutics Development 16
Kyowa Hakko Kirin Co., Ltd. 16
Taiho Pharmaceutical Co., Ltd. 17
Febrile Neutropenia – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
KRN125 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
KRN125 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
YP-18 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AQB-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cefepime - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Meropenem - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mycamine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Febrile Neutropenia Therapeutics – Drug Profile Updates 30
Febrile Neutropenia Therapeutics – Discontinued Products 31
Febrile Neutropenia Therapeutics - Dormant Products 32
Febrile Neutropenia – Product Development Milestones 33
Featured News & Press Releases 33
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Number of Products Under Development for Febrile Neutropenia, H2 2012 7
Products under Development for Febrile Neutropenia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Kyowa Hakko Kirin Co., Ltd., H2 2012 16
Taiho Pharmaceutical Co., Ltd., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Febrile Neutropenia Therapeutics – Drug Profile Updates 30
Febrile Neutropenia Therapeutics – Discontinued Products 31
Febrile Neutropenia Therapeutics – Dormant Products 32

List of Figures
Number of Products under Development for Febrile Neutropenia, H2 2012 7
Products under Development for Febrile Neutropenia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos